Access Pharmaceuticals Awarded Second European Patent for MuGard
DALLAS and NEW YORK, Sept. 12, 2013
-- Company Continues Reinforcing Intellectual Property Protection in
Additional Global Markets
DALLAS and NEW YORK, Sept. 12, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS,
INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received
notification from the European Patent Office that an additional European
patent for MuGard™ has been granted. The patent (EP1997478) protects a wide
range of liquid formulations for the prevention and treatment of mucosal
diseases and disorders.Notification of the grant was published in the
European Patent Bulletin no. 13/36 earlier this month.
"This second patent for MuGard in the EU provides us with additional
protection of the mucoadhesive liquid technology that forms the basis of
MuGard," noted Dr. David Nowotnik, Senior Vice President Research and
Development, Access Pharmaceuticals, Inc. "The new patent also provides us
with additional protection of formulations which could form the basis of
potential MuGard line extension products."
MuGard provides the oral muscosa with a thin protective hydrogel layer which
has been demonstrated in several clinical studies of mucositis to benefit
patients in terms of reduced pain and discomfort as well as a reduction in
objective mucositis scores.
"Our new patent in Europe expands and strengthens our MuGard patent portfolio,
and we anticipate that current and future formulations of MuGard might also
benefit patients with various other ulcerative conditions with the oral cavity
such as oral lichen planus," commented Jeffrey Davis, President and CEO of
Access. "We continue to actively seek a European marketing partner for MuGard,
where MuGard has achieved market clearance and is indicated for the prevention
and management of oral mucositis."
About MuGard: MuGard™ Mucoadhesive Oral Wound Rinse is an oral mucoadhesive
that is designed to manage oral mucositis by forming a protective hydrogel
coating over the oral mucosa to shield the membranes of the mouth and tongue.
In Europe, MuGard is indicated for the prevention of oral mucositis/stomatitis
(that may be caused by radiotherapy and/or chemotherapy) and all types of oral
wounds (mouth sores and injuries), including aphthous ulcers/canker sores and
traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures
About Access : Access Pharmaceuticals, Inc. is an emerging biopharmaceutical
company that develops and commercializes proprietary products for the
treatment and supportive care of cancer patients. Access developed MuGard, a
prescription oral rinse for the management of mucositis and is developing
multiple products, and recently licensed US commercialization rights to AMAG
Pharmaceuticals, Inc. Access also has other advanced drug delivery
technologies including CobaCyte™-mediated targeted delivery and CobOral-oral
drug delivery , its proprietary nanopolymer delivery technology based on the
natural vitamin B12 uptake mechanism. For additional information on Access
Pharmaceuticals, please visit our website at www.accesspharma.com .
This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties. These statements include those relating to:
our cash burn rate, clinical trial plans and timelines and clinical results
for MuGard and Cobalamin, our ability to achieve clinical and commercial
success and our ability to successfully develop marketed products. These
statements are subject to numerous risks, including but not limited to Access'
need to obtain additional financing in order to continue the clinical trial
and operations and to the risks detailed in Access' Annual Reports on Form
10-K and other reports filed by Access with the Securities and Exchange
Company and Media Contact: Christine BerniDirector of Investor Relations
Access Pharmaceuticals, Inc. +1-212-786-6208
Press spacebar to pause and continue. Press esc to stop.